Abstract
[18F] Fluorodeoxyglucose (
F-FDG) PET/CT can improve the staging accuracy and clinical management of patients with hepatobiliary and pancreatic cancers, by detection of unsuspected metastases.
F-FDG PET/CT metabolic parameters are valuable in predicting treatment response and survival. Metabolic response on
F-FDG PET/CT can predict preoperative pathologic response to neoadjuvant therapy in patients with pancreatic cancer and determine prognosis. Several novel non-FDG tracers, such as
Ga prostate-specific membrane antigen (PSMA) and
Ga-fibroblast activation protein inhibitor (FAPI) PET/CT, show promise for imaging hepatobiliary and pancreatic cancers with potential for radioligand therapy.